Send us a text

It is widely accepted that statin drugs reduce cardiovascular risk. However, how much of this risk reduction is attributable to LDL cholesterol reduction as opposed to something intrinsic in the statin drug has been a matter of debate. Paxton takes listeners through a randomized controlled trial that evaluated the efficacy of evolocumab (a biologic PCSK9 ...

The post The Hurry for FOURIER & What’s New From HERDOO2 – Decision Making in VTE and Evolocumab for CVD Risk Reduction appeared first on Healthy Debate.